Affordable Access

Access to the full text

Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma

Authors
  • Sun, Dantong1
  • Liu, Dong1
  • Liu, Qiaoling2
  • Hou, Helei1
  • 1 Qingdao University, China , (China)
  • 2 Qingdao West Coast New Area Central Hospital, China , (China)
Type
Published Article
Journal
Cancer Biology & Therapy
Publisher
Landes Bioscience
Publication Date
Nov 05, 2020
Volume
21
Issue
12
Pages
1097–1104
Identifiers
DOI: 10.1080/15384047.2020.1834319
PMID: 33151119
PMCID: PMC7722699
Source
PubMed Central
Keywords
License
Green

Abstract

Immune checkpoint inhibitors have demonstrated promising efficacy and tolerable safety for advanced malignancies. However, a proportion of patients who had received immunotherapy may experience hyperprogressive disease and a resultant poor prognosis. Here, we report a patient with advanced esophageal squamous carcinoma who developed hyperprogressive disease shortly after immunotherapy. This patient received nivolumab after multiple lines of treatment, including chemotherapy, radiotherapy, and antiangiogenic therapy. Through the comprehensive analysis of NGS results, we concluded that the PI3K/AKT signaling pathway might be associated with hyperprogressive disease after immunotherapy. Additionally, potential mechanisms underlying hyperprogressive disease after immunotherapy reported in other malignant tumors were also summarized.

Report this publication

Statistics

Seen <100 times